CO-DIAGNOSTICS, INC. Form 8-K (March 24, 2022)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated March 24, 2022. Under Item 2.02 the company states that it issued a press release announcing financial results for its fourth quarter and year ended December 31, 2021, furnished as Exhibit 99.1, which includes information regarding its use of a non-GAAP financial measure. Item 7.01 incorporates the Item 2.02 information by reference. The signature block carries /s/ Brian Brown, Chief Financial Officer (Principal Financial and Accounting Officer), dated March 24, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the

Securities
Exchange Act of 1934

Date
of report (Date of earliest event reported): March 24, 2022

CO-DIAGNOSTICS,
INC.

(Exact
name of small business issuer as specified in its charter)

Utah | 1-38148 | 46-2609363
(State
 or other jurisdiction of | (Commission | (IRS
 Employer
incorporation
 or organization) | File
 Number) | Identification
 Number)

2401
S. Foothill Drive , Suite D , Salt Lake City , Utah 84109

(Address
of principal executive offices)

(801) 438-1036

(Issuer’s
telephone number)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

☐ | Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class | Trading
 Symbol(s) | Name
 of each exchange on which registered
Common
 Stock, par value $0.001 per share | CODX | The Nasdaq Capital Market

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ☒

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item
2.02. Results of Operations and Financial Condition.

On
March 24, 2022, Co-Diagnostics, Inc. (the “Company”) issued a press release announcing financial results for its fourth quarter
and year ended December 31, 2021. The full text of the press release, which includes information regarding the Company’s use of
a non-GAAP financial measure, is furnished as Exhibit 99.1 to this Form 8-K.

The
information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore,
the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration
statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference
in such filing.

Item
7.01. Regulation FD. Disclosure.

The
information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits

Exhibit
 No.: | Description:
99.1 | Press Released, dated March 24, 2022
104 | Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS,
 INC.
Date:
 March 24, 2022 | By: | /s/
 Brian Brown
Name: | Brian
 Brown
Title: | Chief
 Financial Officer (Principal
 Financial and Accounting Officer)

File and source

File

SEC_CODX_8-K_filed2022-03-24_0001493152-22-007660.htm

Size

37,653 bytes

SHA-256

2c9a0127038b0841658ad5dc494013378c8f0d6d63dc57549ccbbcb689a3dbd4

Our copy

SEC_CODX_8-K_filed2022-03-24_0001493152-22-007660.htm

Original

www.sec.gov